olaparib Oral Tablet [Lynparza]

Medication research snapshot

CureCurrent currently links 2 distinct registered clinical trials to olaparib Oral Tablet [Lynparza] through its RxNorm intervention mappings. 1 of those studies have the registry status “recruiting” (50%). These are registry statuses, not availability guarantees, study results or evidence of effectiveness.

The leading sponsor shown in this linked dataset is Institut fuer Frauengesundheit, associated with 1 distinct linked trials. This is a count of records, not a ranking of the sponsor's scientific quality.

The highest-count mapped research city in the current result is Berlin, Germany. Only site locations available in the published registry projection are counted; some trial sites may be missing or outdated.

The most common trial-reported condition associated with this drug concept is Breast Cancer (1 linked trials). A registry intervention association is not proof that a drug is approved or effective for that condition.

Numbers are derived from CureCurrent's current ClinicalTrials.gov projection and conservative MONDO/RxNorm mappings. See sources, counting rules and limitations and verify eligibility or clinical findings with the original study record.

Understanding this RxNorm record

RxNorm identifiers distinguish ingredients, specific strengths, dose forms, and branded products. They help connect equivalent terminology across data sources; an RxNorm entry does not by itself establish that a product is currently marketed, approved for a particular use, or appropriate for an individual.

Clinical-trial associations reflect registry-reported intervention names and verified mappings where available. A medication listed in a trial may be investigational for that condition. Consult the original study record and official prescribing information for indications and safety details.

Terminology source: National Library of Medicine RxNorm. Trial source: ClinicalTrials.gov.